Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis

Targeted Oncology

Volumn 11, Issue 3, 2016, Pages 345-351

  Massari, Francesco ^a   Ciccarese, Chiara ^a   Caliò, Anna ^a   Munari, Enrico ^a   Cima, Luca ^a   Porcaro, Antonio Benito ^a   Novella, Giovanni ^a   Artibani, Walter ^a   Sava, Teodoro ^a   Eccher, Albino ^a   Ghimenton, Claudio ^a   Bertoldo, Francesco ^a   Scarpa, Aldo ^a,b   Sperandio, Nicola ^b   Porta, Camillo ^c   Bronte, Vincenzo ^a   Chilosi, Marco ^a   Bogina, Giuseppe ^d   Zamboni, Giuseppe ^d   Tortora, Giampaolo ^a   Samaratunga, Hemamali ^e   Martignoni, Guido ^a   Brunelli, Matteo ^a,b   more..

^a Department of Surgical Science   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c University Hospital Foundation   (Italy)

^d SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE ADENOCARCINOMA; CLINICAL ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; EXPLORATORY RESEARCH; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR INFILTRATING T LYMPHOCYTE; ADENOCARCINOMA; GENETICS; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 84946935007     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-015-0396-3     Document Type: Article

References (39)

1. Gerritsen WR (2012) The evolving role of immunotherapy in prostate cancer. Ann Oncol: Off J Eur Soc Med Oncol/ ESMO 23(Suppl 8):viii22-7. doi:10.1093/annonc/mds259
2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–22. doi:10.1056/NEJMoa1001294
3. Cheng ML, Fong L (2014) Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options in Oncol 15(1):115–26. doi:10.1007/s11864-013-0267-z
4. Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–95
5. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765–72
6. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T et al (2004) PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64(3):1140–5
7. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800. doi:10.1038/nm730
8. Ducloux D (2014) Regulatory T, cells and cancer: an undesired tolerance. Kidney Int 86(1):16–8. doi:10.1038/ki.2014.46
9. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 20(19):5064–74. doi:10.1158/1078-0432.CCR-13-3271
10. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–30. doi:10.1056/NEJMoa1412082
11. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J et al (2014) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28(3):245–53. doi:10.1111/pcmr.12340
12. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–54. doi:10.1056/NEJMoa1200690
13. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–56. doi:10.5858/arpa.2013-0953-SA
14. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer 8(7):823–59. doi:10.1097/JTO.0b013e318290868f
15. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–20. doi:10.1056/NEJMoa041318
16. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–12. doi:10.1056/NEJMoa040720
17. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–54. doi:10.1016/S0140-6736(10)61389-X
18. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005. doi:10.1056/NEJMoa1014618
19. Ryan CJ, Molina A, Griffin T (2013) Abiraterone in metastatic prostate cancer. N Engl J Med 368(15):1458–9. doi:10.1056/NEJMc1301594
20. Beer TM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(18):1755–6. doi:10.1056/NEJMc1410239
21. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–97. doi:10.1056/NEJMoa1207506
22. Parker C, Sartor O (2013) Radium-223 in prostate cancer. N Engl J Med 369(17):1659–60. doi:10.1056/NEJMc1310231
23. Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8(6):467–77. doi:10.1038/nri2326
24. Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24(2):207–12. doi:10.1016/j.coi.2011.12.009
25. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–64. doi:10.1038/nrc3239
26. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–8. doi:10.1038/ni1102-991
27. Westdorp H, Skold AE, Snijer BA, Franik S, Mulder SF, Major PP et al (2014) Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol 5(1):1–15. doi:10.3389/fimmu.2014.00191
28. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D et al (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353(12):1224–35. doi:10.1056/NEJMoa051931
29. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS et al (2005) Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 175(4):2741–53
30. Wilson CA, Mrose SA, Thomas DW (1995) Enhanced production of B lymphocytes after castration. Blood 85(6):1535–9
31. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S et al (2005) Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7(3):239–49. doi:10.1016/j.ccr.2005.01.027
32. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG et al (2001) T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 98(25):14565–70. doi:10.1073/pnas.251140998
33. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F (2009) Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 348(1–2):9–17. doi:10.1016/j.jim.2009.06.004
34. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–23. doi:10.1056/NEJMoa1213755
35. Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T et al (2009) Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 45(9):1664–72. doi:10.1016/j.ejca.2009.02.015
36. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM et al (2007) CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 13(23):6947–58. doi:10.1158/1078-0432.CCR-07-0842
37. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M (2006) Imbalance of regulatory T cells in human autoimmune diseases. Immunology 117(3):289–300. doi:10.1111/j.1365-2567.2005.02317.x
38. Knutson KL, Disis ML, Salazar LG (2007) CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother: CII 56(3):271–85. doi:10.1007/s00262-006-0194-y
39. Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN et al (2015) PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 6(1):234–42